Articles by Ray Dogum

  1. Discovery On Hold: How Shutdowns Stall Science And Shake Trust 10/10/2025

    When the federal government shuts down and appropriations lapse, the ripple effects reach deep into early drug development efforts. FDA slows regulatory intake, NIH freezes grant reviews and awards, clinical trials are disrupted, and talent pipelines tighten as student and work visas remain in limbo.

  2. Tyra Crystallizing The First Oral FGFR3 Therapy For Achondroplasia 9/30/2025

    Tyra Biosciences is using its SNÅP drug discovery platform to develop dabogratinib, the first oral FGFR3-selective therapy for achondroplasia, currently recruiting patients in Phase 2 trials.

  3. AI Meets Aging: Inside The Longevity Revolution With Insilico Medicine (Part 2) 9/19/2025

    Part 2 of 2 - An Interview with Alex (Aleksandrs Zavoronkovs) Zhavoronkov, Ph.D. , Longevity and drug discovery researcher, Founder, CEO and CBO at Insilico Medicine.

  4. AI Meets Aging: Inside The Longevity Revolution With Insilico Medicine (Part 1) 9/18/2025

    An Interview with Alex Zhavoronkov, Ph.D. Longevity and drug discovery researcher, Founder, CEO and CBO at Insilico Medicine. Founded in 2014, Insilico Medicine, is one of the earliest AI-driven biotech companies and one of the few who have pipeline drugs in Phase II trials.

  5. The Death Of A Dogma: David Baltimore And Lessons For Modern Drug Discovery 9/11/2025

    Nobel laureate, David Baltimore passed away at 87 years old, on September 6, 2025. He was widely regarded as a scientific visionary who at just 37, co-discovered reverse transcriptase, an enzyme that flipped molecular biology on its head by showing that genetic information could flow from RNA back to DNA, not just the other way around. 

  6. From Concept To Confidence: A Collaborative Path To Validating NAMs 8/15/2025

    On August 1, 2025, the Foundation for the National Institutes of Health (FNIH) released a Request for Information (RFI) inviting proposals for pilot projects to accelerate the development, validation, and regulatory acceptance of New Approach Methodologies (NAMs). For drug developers, participating in this process offers not only scientific collaboration but also the potential to co-develop regulatory-grade NAMs aligned with FDA and NIH priorities.

  7. The Rise Of NAMs 7/31/2025

    New Approach Methods (NAMs) are rapidly being accepted as replacements for preclinical animal tests long considered to be the gold standard. NAMs include systems of organoids, organs-on-chips, AI-based prediction models, and non-mammalian species.

  8. FDA Leading The Decline Of Animal Testing 7/16/2025

    The gold standard practice of conducting animal studies for evaluating toxicity, pharmacodynamics, and immunogenicity is being challenged by innovative alternatives – New Approach Methods (NAMs).

  9. Five Takeaways from BIO 2025 and Why You Should Stay Tuned 6/26/2025

    New chief editor of Drug Discovery Online shares insights from BIO 2025’s global biotech gathering and spotlights the impacts to early-stage drug research.